<DOC>
	<DOCNO>NCT01133366</DOCNO>
	<brief_summary>The purpose study assess blood clot thin time effect single dose warfarin give alone single dose warfarin give mipomersen ; assess blood level single dose warfarin , single dose mipomersen , single dose warfarin give mipomersen ; ass safety mipomersen give without warfarin .</brief_summary>
	<brief_title>A Study Determine Effects Multiple Doses Mipomersen ( 200 mg SC ) Pharmacodynamics Pharmacokinetics Single-dose Warfarin</brief_title>
	<detailed_description>This Phase 1 , open-label , single-sequence , 2-period , crossover study determine effect multiple dos mipomersen ( 200 mg SC give every day total 4 dos ) PD PK warfarin evaluate PK mipomersen administer alone combination warfarin . Subjects admit clinic Day -1 discharge clinic Day 18 return outpatient visit Days 19 , 20 , 78 . All subject receive single 25-mg oral dose warfarin give alone Day 1 ( designate reference treatment ) . All subject receive 200-mg SC dose mipomersen give every day Days 8 , 10 , 12 , 14 ( total 800 mg mipomersen ) single 25-mg oral dose warfarin also give Day 14 ( combination designate test treatment ) .</detailed_description>
	<mesh_term>Mipomersen</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Written inform consent studyrelated procedure perform . Body mass index ( BMI ) 18 32 kg/m2 , inclusive . No clinically significant abnormality base medical history , laboratory assessment , vital sign , 12lead electrocardiogram ( ECG ) result , physical examination . Subjects willing able follow prescribe diet . Subjects consume nicotine nicotinecontaining product least 6 month Screening . Subjects nonpregnant nonlactating , surgically sterile , postmenopausal , abstinent , subject partner willing use reliable method contraception study 5 month mipomersen dose . Poor metabolizer warfarin determine CYP2C9 genotype test . Clinically significant PT , aPTT , INR , protein C , protein S , platelet count result hematuria . Abnormal prolongation skin bleeding time personal family history coagulation bleed disorder , vascular malformation include aneurysm , venous thromboembolism . Active recur clinically significant cardiovascular , pulmonary , renal , endocrine , hepatic , neurologic , psychiatric , immunologic , hematologic , gastrointestinal , metabolic disease . Active malignancy type nonmelanomatous skin malignancy . Use prescribed overthecounter concomitant medication within 14 day first dose investigational product without approval Investigator Sponsor . Positive test result drug abuse , alcohol , cotinine history alcohol abuse drug addiction . Positive test result hepatitis B surface antigen , hepatitis C virus antibody , HIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ISIS301012</keyword>
	<keyword>antisense</keyword>
	<keyword>ApoB ( Apolipoprotein B )</keyword>
	<keyword>LDL ( low density lipoprotein )</keyword>
	<keyword>mipomersen</keyword>
</DOC>